Cancer Immunotherapies Targeting Tumor-Associated Regulatory T Cells

Onco Targets Ther. 2019 Dec 13:12:11033-11044. doi: 10.2147/OTT.S231052. eCollection 2019.

Abstract

Tumor-associated regulatory T cells (Tregs) are important effectors in the tumor microenvironment (TME), acting as accomplices in the promotion of tumor progression. Currently, the importance of removing the immunosuppressive activity in the TME has received its due attention, and Tregs have been focused on. The cytokine-receptor axes are among the essential signaling pathways in immunocytes, and tumor-associated Tregs are no exception. Therefore, manipulating cytokine-receptor pathways may be a promising effective strategy for treating various malignancies. Here, we summarize the classification, immunosuppressive mechanisms, existing immunotherapies, and potential biomarkers related to tumor-infiltrating Tregs to guide the development of effective cancer immunotherapies.

Keywords: Tregs; biomarkers; cancer immunotherapies; chemokine receptors; immune suppression.

Publication types

  • Review